Barclays
SPTX

Barclays’s Seaport Therapeutics SPTX Stock Holding History

Barclays’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2K Buy
+837
New +$14.7K ﹤0.01% 4603

Other funds holding SPTX

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barclays's SPTX Position: Q2 2026 in Review

Barclays opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 837 shares worth $18.2K. The stake represents ﹤0.01% of the portfolio and ranks #4603 among its holdings.

54 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

  • Barclays held 837 shares of Seaport Therapeutics worth $18.2K as of Q2 2026.
  • Seaport Therapeutics was a new Barclays position in Q2 2026.
  • Seaport Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4603 holding.
  • 54 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.